Mortality In Mind: Survival Analysis Drove Esbriet, Ofev Reviews, If Not Labels
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neither Esbriet sponsor InterMune nor Ofev sponsor Boehringer Ingelheim chose to follow FDA’s advice to use mortality as the primary endpoint for trials in IPF, but exploratory survival findings were nonetheless key to approval of both drugs – even though the mortality data barely appear in labeling.
You may also be interested in...
US FDA's Breakthrough Program Needs Higher Standard For Comparators, NEJM Says
Harvard Medical School researchers call for inclusion of off-label drugs, accelerated approvals, and dietary supplements in the definition of 'existing therapies.'
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.